<DOC>
	<DOCNO>NCT00136604</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity , safety reactogenicity booster dose DTPw-HBV/Hib-MenAC compare DTPw-HBV/Hib give healthy subject 15 24 month age prim 3 dos Tritanrix™-HepB/Hib-MenAC study 100480 . Antibody persistence evaluate 24 30 month . Immunogenicity , safety reactogenicity dose Mencevax™ ACWY give 24 30 month also evaluate give subject boost MenA conjugate and/or MenC contain vaccine .</brief_summary>
	<brief_title>Response GSK Biologicals ' Tritanrix-HepB/Hib-MenAC Vacc ( 4th Dose ) 15-24m &amp; Mencevax ACWY 24-30m</brief_title>
	<detailed_description>This study conduct two stage . In DTP booster phase subject receive booster dose Tritanrix™-HepB/Hib-MenAC Tritanrix™-HepB/Hib ( active control ) 15 24 month single-blind manner subject ' parent know vaccine administer child ( booster phase longer recruiting ) . In Mencevax™ ACWY phase 24-30 month dose Mencevax™ ACWY give subject boost MenA conjugate and/or MenC contain vaccine 15-24 month open manner ( booster phase yet recruit ) . Up four blood sample take : one month administration DTP booster dose Mencevax™ ACWY . To comply immunisation calender Thailand , 15-24 month subject receive OPV . At 16-25 month 2 dos Japanese Encephalitis ( JE ) vaccine dose varicella vaccine offer 25-31 month dose varicella JE vaccine offer .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<criteria>Inclusion criterion : Healthy male female include 15 24 month age Having participate primary vaccination study DTPWHBV=HIBMENACTT003 ( eTrack No . 100480 ) Exclusion criterion : Booster vaccination diphtheria , tetanus , pertussis , hepatitis B , Haemophilus influenzae type b ( Hib ) and/or meningococcal serogroups A and/or C disease foreseen protocol , date study conclusion visit primary vaccination study DTPWHBV=HIBMENACTT003 ( eTrack No . 100480 ) . History known exposure diphtheria , tetanus , pertussis , hepatitis B , Hib and/or meningococcal serogroup A C disease . Any confirm suspected immunosuppressive immunodeficient condition . A family history congenital hereditary immunodeficiency . Major congenital defect serious chronic illness . History neurologic disorder seizure include febrile seizure ( least two event ) infancy .</criteria>
	<gender>All</gender>
	<minimum_age>427 Days</minimum_age>
	<maximum_age>730 Days</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prophylaxis diphtheria</keyword>
	<keyword>Hib &amp; meningococcal serogroup A &amp; C disease</keyword>
</DOC>